Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study
2
Issued Date
2023-07-01
Resource Type
ISSN
18762018
eISSN
18762026
Scopus ID
2-s2.0-85157964352
Journal Title
Asian Journal of Psychiatry
Volume
85
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Journal of Psychiatry Vol.85 (2023)
Suggested Citation
Chen C.K., Yang S.Y., Park S.C., Jang O.J., Zhu X., Xiang Y.T., Ouyang W.C., Javed A., Khan M.N.S., Grover S., Avasthi A., Kallivayalil R.A., Chee K.Y., Chemi N., Kato T.A., Hayakawa K., Pariwatcharakul P., Maramis M., Seneviratne L., Sim K., Tang W.K., Oo T., Sartorius N., Tan C.H., Chong M.Y., Park Y.C., Shinfuku N., Lin S.K. Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study. Asian Journal of Psychiatry Vol.85 (2023). doi:10.1016/j.ajp.2023.103613 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/81576
Title
Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study
Author(s)
Chen C.K.
Yang S.Y.
Park S.C.
Jang O.J.
Zhu X.
Xiang Y.T.
Ouyang W.C.
Javed A.
Khan M.N.S.
Grover S.
Avasthi A.
Kallivayalil R.A.
Chee K.Y.
Chemi N.
Kato T.A.
Hayakawa K.
Pariwatcharakul P.
Maramis M.
Seneviratne L.
Sim K.
Tang W.K.
Oo T.
Sartorius N.
Tan C.H.
Chong M.Y.
Park Y.C.
Shinfuku N.
Lin S.K.
Yang S.Y.
Park S.C.
Jang O.J.
Zhu X.
Xiang Y.T.
Ouyang W.C.
Javed A.
Khan M.N.S.
Grover S.
Avasthi A.
Kallivayalil R.A.
Chee K.Y.
Chemi N.
Kato T.A.
Hayakawa K.
Pariwatcharakul P.
Maramis M.
Seneviratne L.
Sim K.
Tang W.K.
Oo T.
Sartorius N.
Tan C.H.
Chong M.Y.
Park Y.C.
Shinfuku N.
Lin S.K.
Author's Affiliation
Chang Gung University School of Medicine
Faculty of Health Sciences
Siriraj Hospital
Graduate School of Medical Sciences
The Affiliated Guangji Hospital of Soochow University
University of Sri Jayewardenepura
Hanyang University Guri Hospital
University of Yangon
Services Institute of Medical Sciences Lahore
Universitas Airlangga
Chang Gung Memorial Hospital
Hanyang University College of Medicine
Taipei City Hospital Taiwan
Kuala Lumpur Hospital
Seinan Gakuin University
National University of Singapore
Kaohsiung Medical University
Singapore Institute of Mental Health
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Health Management International
Pushpagiri Institute of Medical Sciences
Shu-Zen Junior College of Medicine and Management
Association for the Improvement of Mental Health Programs (AMH)
Pakistan Psychiatric Research Centre
Bugok National Hospital
Jianan Psychiatric Center
Regency Specialist Hospital
Hospital Kajang
Faculty of Health Sciences
Siriraj Hospital
Graduate School of Medical Sciences
The Affiliated Guangji Hospital of Soochow University
University of Sri Jayewardenepura
Hanyang University Guri Hospital
University of Yangon
Services Institute of Medical Sciences Lahore
Universitas Airlangga
Chang Gung Memorial Hospital
Hanyang University College of Medicine
Taipei City Hospital Taiwan
Kuala Lumpur Hospital
Seinan Gakuin University
National University of Singapore
Kaohsiung Medical University
Singapore Institute of Mental Health
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Health Management International
Pushpagiri Institute of Medical Sciences
Shu-Zen Junior College of Medicine and Management
Association for the Improvement of Mental Health Programs (AMH)
Pakistan Psychiatric Research Centre
Bugok National Hospital
Jianan Psychiatric Center
Regency Specialist Hospital
Hospital Kajang
Other Contributor(s)
Abstract
Objective: Mood stabilizers are psychotropic drugs mainly used to treat bipolar disorder in the acute phase or for maintenance therapy to prevent relapse. In clinical practice, mood stabilizers are commonly prescribed for conditions other than bipolar disorder. This study investigated the distribution of mood stabilizer prescriptions for different psychiatric diagnoses and studied differences in the drugs, dosage, and plasma concentration in 10 Asian countries including Taiwan, South Korea, Malaysia, China, Thailand, India, Pakistan, Singapore, Indonesia, and Myanmar. Methods: Patients prescribed mood stabilizers (lithium, carbamazepine, valproic acid, or lamotrigine) for a psychiatric condition other than bipolar disorder (codes F31.0–F31.9 in the International Classification of Diseases, 10th Edition, Clinical Modification) were recruited through convenience sampling. A website-based data entry system was used for data collection. Results: In total, 1557 psychiatric patients were enrolled. Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F20-F29, 55.8 %) was the most common diagnosis, followed by non-bipolar mood disorders (F30, F31- F39, 25.3 %), organic mental disorder (F00-F09, 8.8 %), mental retardation (F70-F79, 5.8 %) and anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders (F40-F48, 4.4 %). The most frequently targeted symptoms (>20 %) were irritability (48 %), impulsivity (32.4 %), aggression (29.2 %), anger (20.8 %), and psychosis (24.1 %). Valproic acid was the most frequently used medication. Conclusions: Clinicians typically prescribe mood stabilizers as empirically supported treatment to manage mood symptoms in patients with diagnoses other than bipolar disorders, though there is on official indication for these disorders. The costs and benefits of this add-on symptomatic treatment warrant further investigation.